drugset / Trial / NCT03301805
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy at the recommended dose.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2027-04-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BLEX 404 | Unknown | 3 mg/kg | Oral |
| Subject | BLEX 404 | Unknown | 10 mg/kg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |